Pharos Pharmaceuticals, Inc. is engaged in research and development
of proprietary therapeutic products for treatment of inflammatory
and immunological diseases, with a goal to their commercialization
in association with major pharmaceutical companies.
Pharos major asset
is its US Patent 5,631,245
for Diosamine, a carbohydrate drug at pre-clinical stage of development.
Diosamine is a non-specific immune modulator for therapeutic use
that reverses inflammation and improper cell-mediated immunity.
ENBDK, another discovery, is a precursor molecule of Diosamine
where efficacy is highly dependent on the synthesis of the final
compound by the organism of a healthy individual.
The business potential
of Diosamine is as an
oral drug for the treatment and prevention of inflammatory diseases
and improper mediated immunity. The drug should restore to normal
the proper functioning of a system in the human organism, treat
a common factor of several diverse diseases and deal with hyper
and improper inflammatory reactions affecting the immunological
system. Its expected clinical uses are as differentiated topical
drug for the treatment and prevention of hyper reactions to infectious
diseases such as herpes; allergies and autoimmune disorders of
the skin like psoriasis, eczema and scleroderma; and trauma related
matters such as surgical incisions, ulcers, wounds, cosmetic surgery
|DC&G Investments, S.A. -
Av. A. Moreau de Justo 1150
Of. B204, Dock 8, Puerto Madero - C1107AAX Buenos Aires,
Tel: (5411) 4343-3133 Fax: (5411) 4343-3366